July 11, 2018
2 min read
Save

Top stories in endocrinology: switch from analogue to insulin reduces part D coverage gap, #MeToo era highlights need to address disparities and harassment

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Among the top stories in endocrinology is the need to work harder to address gender disparities and reports of harassment in the #MeToo era. Medicare beneficiaries with type 2 diabetes who switched from analogue to human insulin were less likely to reach the spending limit for their Part D drug plan. Other top stories include a 10-week treatment with a higher dose of hydrocortisone lowered the metabolism of tryptophan for patients with secondary adrenal insufficiency, transgender women who initiated cross-sex estrogen therapy were at increased risk for acute cardiovascular events compared with cisgender women who initiated similar hormone therapy, and the use of continuous glucose monitoring for patients with type 1 and 2 diabetes was associated with lower health care costs and adherence vs. self-monitoring blood glucose.

In #MeToo era, ‘blind spots’ persist in endocrinology, clinical sciences

As the #MeToo era brings a heightened awareness to endocrinology, academic medicine and the clinical sciences, important gender disparities and reports of harassment continue to persist, challenging everyone to work harder to tackle the issue, according to two speakers at the American Diabetes Association annual meeting. Read More.

Switch from analogue to human insulin reduces part D coverage gap risk for Medicare beneficiaries

Medicare beneficiaries with type 2 diabetes switched from analogue to human insulin were less likely to reach the spending limit for their Part D drug plan with no changes in hospitalization rates for hypoglycemia or hyperglycemia and only a slightly increased mean HbA1c, according to a presentation at the American Diabetes Association annual meeting. Read More.

Higher-dose hydrocortisone may reduce symptoms in secondary adrenal insuffi ci ency

Among patients with secondary adrenal insufficiency, a 10-week treatment with a higher dose of hydrocortisone lowered the metabolism of tryptophan, mediating the effects of the drug on fatigue and physical functioning, according to findings from a double-blind crossover study. Read More.

In transgender women, estrogen therapy may increase risk for VTE

Transgender women who initiated cross-sex estrogen therapy were at increased risk for acute cardiovascular events, including venous thromboembolism and stroke, compared with cisgender women who initiated similar hormone therapy, according to a health care database analysis published in the Annals of Internal Medicine. Read More.

CGM lowers health care costs, improves adherence vs. SMBG

Among patients with type 1 and type 2 diabetes prescribed multiple daily injection therapy, the use of continuous glucose monitoring was associated with lower health care costs and improved adherence vs. self-monitoring blood glucose, according to findings. Read More.

PAGE BREAK